🤧 Paxlovid Mechanism & Rebound Phenomenon Simulator
This simulator illustrates how nirmatrelvir/ritonavir works to inhibit viral protease in cases of COVID-19, and explains the mechanism behind symptom rebound after completing a course of treatment.
Nirmatrelvir Blocks the Main Viral Protease
A short placeholder sentence on protease inhibition mechanism.
- 3CLpro: Target enzyme (Placeholder short note)
- Covalent: Inhibitor type (Placeholder short note)
- Active site: Binding site (Placeholder short note)
- Ritonavir: Booster drug (Placeholder short note)
How nirmatrelvir stops the protease
Placeholder sentence describing active-site binding and polyprotein cleavage blockade.
Fixed Five-Day Dosing Schedule
A short placeholder sentence on the standard dosing regimen.
- 5 days: Course length (Placeholder short note)
- 2x daily: Dosing (Placeholder short note)
- ≤5 days: Start window (Placeholder short note)
- CYP3A4 boost: Ritonavir role (Placeholder short note)
Why ritonavir boosting matters
Placeholder sentence describing CYP3A4 inhibition extending nirmatrelvir exposure.
Rapid Drop in Viral Load During Therapy
A short placeholder sentence on suppression kinetics.
- ~3 logs: Load drop (Placeholder short note)
- Day 1-3: Onset (Placeholder short note)
- Faster drop: Adherence effect (Placeholder short note)
- ~1-2 days: Symptom lag (Placeholder short note)
Replication halted, load falls
Placeholder sentence describing rapid decline in detectable viral RNA.
Viral and Symptom Rebound After Stopping
A short placeholder sentence on the rebound mechanism.
- Day 7-9: Rebound window (Placeholder short note)
- ~10-20%: Reported rate (Placeholder short note)
- Incomplete clearance: Cause theory (Placeholder short note)
- Not routine: Retreatment (Placeholder short note)
Why rebound happens
Placeholder sentence describing residual virus reemerging after drug clearance.
Placeholder short callout about rebound not requiring a second antiviral course.
Final Clearance and Symptom Resolution
A short placeholder sentence on eventual full recovery.
- Day 10+: Resolution (Placeholder short note)
- Adaptive clearance: Immune role (Placeholder short note)
- Until negative: Isolation (Placeholder short note)
- Full recovery: Outcome (Placeholder short note)
Immune system finishes the job
Placeholder sentence describing adaptive immunity clearing residual virus.
This simulator illustrates how nirmatrelvir/ritonavir works to inhibit viral protease in cases of COVID-19, and explains the mechanism behind symptom rebound after completing a course of treatment.
2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install